Abstract
2025
Acrocyanosis After Immunotherapy: Vasculitis or Vasculopathy? Emergence of a New Iatrogenic Disease: Case series from CanRIO.
View Abstract
Scientific Abstracts
Conference abstracts and presentations by CanRIO members sharing the latest research findings on rheumatic immune-related adverse events.
14 abstracts
Filter by conference
Abstract
2025
Immune Checkpoint Inhibitors in Patients with Pre-Existing Rheumatic Disease and the Impact of Immunosuppression: Data from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
View Abstract
Abstract
2025
Baseline Immunosuppression and Cancer Survival in Patients with Pre-Existing Rheumatic Disease treated with Immune Checkpoint Inhibitors: Data from CanRIO.
View Abstract
Abstract
2025
Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
View Abstract
Abstract
2025
Description of Immune Checkpoint Inhibitor Associated Sicca-Like Syndrome from the Canadian Research Group of Rheumatology in Immuno-Oncology Database: A Case Series
View Abstract
Abstract
2024
Impact of Age on Rheumatic Immune-related Adverse Events: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
View Abstract
Abstract
2023
Cancer Outcomes in Cancer Patients with Immune Checkpoint Inhibitor-induced Inflammatory Arthritis Treated with Glucocorticoids: Data from the CanRIO Retrospective Cohort
View Abstract
Abstract
2023
The Effect of Sex on Patients with Pre- Existing Rheumatoid Arthritis and ICI-Induced Inflammatory Arthritis: Data from the CanRIO Prospective Cohort.
View Abstract
Abstract
2023
Impact of Immunosuppression on the Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Rheumatic Autoimmune Disease: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
View Abstract
Abstract
2023
Utilization of a New Educational Platform to Improve the Care of Cancer Patients Receiving Immunotherapy: An Initiative of CanRIO.
View Abstract
Abstract
2023
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Rheumatic Autoimmune Disease: Experience from CanRIO.
View Abstract
Abstract
2023
Impact of Aging on Rheumatic Immune-related Adverse Events Secondary to Immune Checkpoint Inhibitors: Experience from CanRIO.
View Abstract
Abstract
2023
Outcomes and Predictors of Chronic ICI- Induced Inflammatory Arthritis: Data from the CanRIO Retrospective Cohort.
View Abstract
Abstract
2023
CanRIO — A Retrospective Chart Review Study of Adults with Inflammatory Arthritis Associated with Cancer Immunotherapies.
View Abstract